News Sentiment

ICCM sentiment intelligence

Icecure Medical news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 5.40 Week of 19 Jun 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 61

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+125.9% over one week, -23.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

This Undervalued Medical-Devices Stock Is Poised for a Rebound

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 125.9% Price confirming higher
Trend fit Trend inactive -23.4% over four weeks
Fair value -79.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 39
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 61
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 17
Stock Titan 11
PR Newswire 7
GuruFocus 3
TechStock² 2
Benzinga 2
TradingView 2
StockStory 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 21
Macro sensitivity 2
Regulatory and legal 2
Deals and strategy 1
Guidance 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
Stock Titan Direct company coverage

IceCure Medical (ICCM) prices $5.5M private placement with warrant package

IceCure Medical (ICCM) has priced a $5.5 million private placement with a single institutional investor, involving the issuance of pre-funded warrants and new Series D and E warrants. The company also announced a 70% increase in its active U.S. commercial ProSense® install base f

Tone
Positive 64/100
Event
Market update
Published
18 Jun 2026 21:11
Source
Stock Titan
Mugglehead Investment Magazine Direct company coverage

Tumour freezing specialist IceCure Medical skyrockets from latest successes

IceCure Medical Ltd (NASDAQ: ICCM), a company specializing in cryoablation technology for tumors, has seen its shares soar after announcing a 70% increase in its US commercial install base for its ProSense system and a US$5.5 million private placement. The ProSense system uses li

Tone
Positive 92/100
Event
Market update
Published
18 Jun 2026 08:40
Source
Mugglehead Investment Magazine
StreetInsider Direct company coverage

IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance

IceCure Medical Ltd. reported a 70% increase in its U.S. active commercial install base for ProSense® breast cancer cryoablation systems since receiving FDA marketing authorization in October 2025. This growth is attributed to accelerating commercial adoption, expanding physician

Tone
Positive 74/100
Event
Market update
Published
17 Jun 2026 20:10
Source
StreetInsider
Benzinga Direct company coverage

IceCure Stock Surges After 70% ProSense Install Increase

IceCure Medical (NASDAQ: ICCM) stock surged after the company announced a 70% increase in its U.S. ProSense install base following FDA marketing authorization in October 2025. This growth reflects accelerated commercial adoption, rising physician demand, and broader expansion int

Tone
Positive 70/100
Event
Macro sensitivity
Published
17 Jun 2026 17:10
Source
Benzinga
Stock Titan Direct company coverage

IceCure lands $5.5M healthcare investor deal at a premium

IceCure Medical Ltd. (ICCM) announced a private placement totaling $5.5 million with a single healthcare institutional investor. The deal involves the sale of ordinary shares, Series D warrants, and Series E warrants at a combined purchase price of $3.00 per share, a premium to i

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 17:10
Source
Stock Titan
PR Newswire Direct company coverage

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

IceCure Medical (ICCM) has announced a $5.5 million private placement with a single healthcare-focused institutional investor. The placement involves the sale of ordinary shares and accompanying warrants at $3.00 per share, a premium to the Nasdaq closing price. The proceeds are

Tone
Positive 66/100
Event
Market update
Published
17 Jun 2026 17:10
Source
PR Newswire
TradingView Direct company coverage

ICCM Stock On Track For Best Day In Nearly 5 Years — What’s Driving The 200% Rally?

Shares of IceCure Medical Ltd. (ICCM) surged over 200% on Wednesday following positive news about the accelerated adoption of its ProSense system in the U.S. The company reported a 70% increase in active U.S. commercial installs of ProSense since its FDA marketing authorization i

Tone
Positive 91/100
Event
Market update
Published
17 Jun 2026 16:39
Source
TradingView
TechStock² Direct company coverage

IceCure Medical jumps on U.S. ProSense install base growth after FDA clearance

IceCure Medical shares surged after the company announced a 70% increase in the U.S. commercial install base for its ProSense cryoablation system in breast cancer since FDA marketing approval in October 2025. This growth follows a 1-for-30 reverse stock split aimed at regaining N

Tone
Positive 71/100
Event
Regulatory and legal
Published
17 Jun 2026 16:10
Source
TechStock²
StocksToTrade Direct company coverage

ICCM Stock Explodes As New Cancer Data Fuels Trading Frenzy

IceCure Medical Ltd. (ICCM) stock surged by 235.21% due to positive clinical data for its ProSense cryoablation system, including nearly 90% recurrence-free outcomes in small kidney tumors and promising results in breast cancer and fibroadenomas. This data, coupled with recent FD

Tone
Positive 95/100
Event
Earnings
Published
17 Jun 2026 14:10
Source
StocksToTrade
Stock Titan Direct company coverage

FDA clearance drives 70% jump in IceCure’s U.S. ProSense base

IceCure (NASDAQ: ICCM) reported a 70% increase in its active U.S. commercial install base for the ProSense® system, used for breast cancer cryoablation, following FDA marketing authorization in October 2025. This growth is attributed to updated ASBrS clinical guidance, increased

Tone
Positive 61/100
Event
Guidance
Published
17 Jun 2026 12:39
Source
Stock Titan
Benzinga Direct company coverage

Icecure Medical Analyst Ratings and Price Targets | NASDAQ:ICCM

Icecure Medical (NASDAQ: ICCM) has a consensus price target of $2.13 based on ratings from three analysts, with a high of $2.90 and a low of $1.00. The average price target from the three most recent analyst ratings — Maxim Group and HC Wainwright & Co. — implies a significant do

Tone
Negative 39/100
Event
Analyst action
Published
05 Jun 2026 15:39
Source
Benzinga
MSN Direct company coverage

IceCure Medical to boost share price with 1-for-30 reverse split to regain NASDAQ compliance

IceCure Medical (ICCM) announced a 1-for-30 reverse stock split to increase its share price and regain compliance with Nasdaq's minimum bid price requirement. The reverse stock split is expected to become effective around June 12, 2026, with trading on a split-adjusted basis comm

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 01:39
Source
MSN
GuruFocus Direct company coverage

IceCure Medical (ICCM) Announces 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing

IceCure Medical (ICCM) has announced a 1-for-30 reverse stock split, effective June 4, 2026, to raise its stock price above Nasdaq's minimum $1 bid requirement and maintain its listing. The split will reduce outstanding shares from 84.2 million to approximately 2.8 million, with

Tone
Negative 30/100
Event
Market update
Published
03 Jun 2026 01:39
Source
GuruFocus
GuruFocus Direct company coverage

IceCure Medical (ICCM) Announces 1-for-30 Reverse Stock Split to Meet Nasdaq Requirements

IceCure Medical (ICCM) has announced a 1-for-30 reverse stock split to meet Nasdaq's minimum bid price requirement of $1.00 per share. The company, which specializes in cryoablation technology, is considered undervalued by GuruFocus with a GF Value of $0.72 against a current pric

Tone
Positive 65/100
Event
Market update
Published
02 Jun 2026 19:39
Source
GuruFocus
Stock Titan Direct company coverage

IceCure Medical (NASDAQ: ICCM) implements 1-for-30 reverse share split for Nasdaq

IceCure Medical (NASDAQ: ICCM) is implementing a 1-for-30 reverse share split to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split will reduce outstanding shares from approximately 84.2 million to 2.8 million and will commence trading on a split-adjus

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 13:39
Source
Stock Titan
PR Newswire Direct company coverage

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

IceCure Medical Ltd. has announced a 1-for-30 reverse share split to proactively regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split will take effect on June 4, 2026, and will adjust the number of outstanding shares from approximately 84.2 million to 2.

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 12:29
Source
PR Newswire
Stock Titan Direct company coverage

IceCure consolidates shares 30-to-1 in bid to keep Nasdaq listing

IceCure Medical (ICCM) announced a 1-for-30 reverse share split to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split will reduce outstanding shares from approximately 84.2 million to 2.8 million and will be effective on June 4, 2026. Despite recent po

Tone
Negative 36/100
Event
Market update
Published
02 Jun 2026 12:29
Source
Stock Titan
TradingView Direct company coverage

Number of shareholders of IceCure Medical Ltd. – BOATS:ICCM

This article focuses on IceCure Medical Ltd. (ICCM) listed on the Blue Ocean Alternative Trade System (BOATS). It specifically aims to provide information regarding the number of shareholders for the company, although the content section for this data is currently empty. The arti

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 14:09
Source
TradingView
Stock Titan Direct company coverage

[Form 4] IceCure Medical Ltd. Insider Trading Activity

This article reports on an insider trading activity filing (Form 4) for IceCure Medical Ltd. (ICCM) dated May 18, 2026. The filing indicates that Ronen Tsimerman, the former Chief Financial Officer, ceased serving in his role on May 17, 2026, and is therefore no longer subject to

Tone
Neutral 50/100
Event
Market update
Published
21 May 2026 22:39
Source
Stock Titan
www.marketscreener.com Direct company coverage

IceCure Medical Ltd. Reports Nearly 90% Recurrence-Free Rate For Cryoablation Of Kidney Cancer And Showcases ProSense At ECIO 2026

IceCure Medical Ltd. announced impressive results for its ProSense cryoablation system at ECIO 2026, highlighting an 89.4% recurrence-free rate for kidney cancer patients with tumors measuring 3 cm or less. The company also showcased positive data for breast cancer and fibroadeno

Tone
Positive 72/100
Event
Earnings
Published
19 May 2026 20:39
Source
www.marketscreener.com